Thumbnail Image
Publication

Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): an interim review of REASSURE

Sternberg, C
; 
Tombal, B
; 
Miller, K
; 
Saad, F
; 
Sartor, O
; 
Sade, J
; 
Logothetis, C
; 
Bellmunt, J
; 
Dizdarevic, S
; 
Harshman, L
... show 8 more
Citations
Altmetric:
Abstract
Authors
Sternberg, C
Tombal, B
Miller, K
Saad, F
Sartor, O
Sade, J
Logothetis, C
Bellmunt, J
Dizdarevic, S
Harshman, L
Logue, John P
Baldari, S
Richardson, T
Bottomley, D
Schostak, M
Bayh, I
Kalinovsky, J
Higano, C
Affiliation
Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy
Description
Date
2018
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
From UNPAYWALL
Adobe PDF, 76.76 KB
Keywords
Type
Meetings and Proceedings
Citation
Sternberg CN, Tombal B, Miller K, Saad F, Sartor O, Sade JP, et al. 826P Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): an interim review of REASSURE. Ann Oncol. 2018;29(suppl_8):288.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/621805
Embedded videos